

4CPS-230



Mayo López, C; Henares López, A; Carrasco Piernavieja, L Fernández Caballero, R; Collados Arroyo, V.
 Hospital Infanta Elena. Hospital Pharmacy. Madrid (Valdemoro) SPAIN

BACKGROUND AND IMPORTANCE

Monoclonal antibodies directed against PCSK9 protein revolutionized the treatment for hypercholesterolaemia (HC) 5 years ago. It is necessary to review the effectiveness data over time in real clinical practice.

AIM AND OBJECTIVES

To find out the evolution over time of the effectiveness of for HC treatment with PCSK9 inhibitors (iPCSK9) (alirocumab/evolocumab).

MATERIAL AND METHODS Observational, retrospective, analytical and descriptive study in a second-level hospital including patients diagnosed with HC who started treatment with IPCSK9 (Sept 2017-March 2023). Using Kaplan-Meier curve analysis and Mantel-Haenszel test with STATA software.

Patients > 18 years
At least 12 months

Alirocumab 75 mg/14 days
 Alirocumab 150 mg/month
 Alirocumab 150 mg/14 days
 Evolocumab 140 mg/14 days

Age

LDL levels (mg/dL) (0/1/3/6/12m)

Reaching target date

Start/End treatment date

Sex

Target LDL levels (100/70/55 mg/dL)

Reaching 50% basal LDL reduction date

Treatment change date



RESULTS N=40

67,5% 62,5 years old Median (IQR:55,1-71,7)

basal LDL 148,5 mg/dL (IQR:111,5-189,5)

50% ALIROCUMAB 75mg/14d **22,5%** ALIROCUMAB 150mg/m

27,5% EVOLOCUMAB



	1 month	3 months	6 months	12 months	p value
Likelihood of reaching LDL target (%)	25	4.7	57.8	67.7	p=0.74*
Likelihood of 50% reduction LDLb (%)	25	40	51.4	60	p=0.59**

*Applying the Mantel-Cox test confirms the absence of differences between the different dosages studied (p=0.74).

** The curve shows a clear tendency for evolocumab to be faster in achieving the 50% LDLb reduction.

At 14 months, at least 50% of patients needed to intensify alirocumab dosing

CONCLUSIONS

IPCSK9 have proven to be effective drugs in a short period of time for the treatment of hypercholesterolaemia, with 50% of patients reaching target LDL levels within 6 months. Those patients on alirocumab treatment have on average needed to intensify dosing in just over a year, however the baseline dose(150mg/month) has been proven more effective over time. Evolocumab seems to be faster in achieving the 50% of LDL reduction.